Met Life Investment Management, LLC Arcellx, Inc. Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 26,058 shares of ACLX stock, worth $1.66 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
26,058
Previous 24,981
4.31%
Holding current value
$1.66 Million
Previous $2.09 Million
4.89%
% of portfolio
0.01%
Previous 0.01%
Shares
15 transactions
Others Institutions Holding ACLX
# of Institutions
227Shares Held
45MCall Options Held
450KPut Options Held
647K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$279 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$239 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$224 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$222 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$212 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.79B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...